ImmunityBio (NASDAQ:IBRX) Hits New 52-Week High – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX)’s share price hit a new 52-week high during trading on Thursday . The company traded as high as $8.28 and last traded at $7.2680, with a volume of 34566229 shares changing hands. The stock had previously closed at $6.92.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA meeting gave a defined path to resubmit an sBLA for ANKTIVA and ImmunityBio said it will file additional information within 30 days — a direct regulatory catalyst supporting upside. FDA Talks Set Path For Expanded Use For ImmunityBio’s Anktiva In Bladder Cancer
• Positive Sentiment: H.C. Wainwright reiterated bullish coverage and raised long‑term estimates (FY2030 EPS outlook increased), signaling growing analyst confidence that supports investor interest. H.C. Wainwright Affirms Buy Rating for ImmunityBio
• Positive Sentiment: Multiple broker notes and “buy” ratings with higher targets have circulated in recent days, reinforcing speculative buying and momentum among retail/long investors. MarketBeat IBRX Coverage
• Neutral Sentiment: Short sellers are being pressured by the rapid run-up, which can accelerate moves via forced covering but is a technical, not fundamental, support for the rally. Stock Market Today: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: The share price has run for multiple sessions (reported as a 12‑day streak in some outlets) and much of today’s upside reflects momentum and heavy volume rather than new clinical trial results. ImmunityBio rockets on 12th day
• Negative Sentiment: Insiders have sold shares recently — director Christobel Selecky sold 25,000 shares at ~$7.51 (and previously 50,000 at ~$5), and director Barry J. Simon sold ~151,967 shares — actions investors often interpret as profit‑taking or diversification. ImmunityBio Director Sells Stock
• Negative Sentiment: Prominent commentators (e.g., Jim Cramer) have advised taking profits amid the froth, highlighting momentum risk and the chance that regulatory follow‑ups could require more time/data than the market expects. Jim Cramer on ImmunityBio

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Piper Sandler raised their price objective on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday. D. Boral Capital reiterated a “buy” rating and issued a $24.00 target price on shares of ImmunityBio in a research report on Tuesday. Jefferies Financial Group boosted their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.00.

ImmunityBio Stock Performance

The firm has a market cap of $7.02 billion, a PE ratio of -17.33 and a beta of 0.03. The firm’s 50 day moving average price is $2.54 and its two-hundred day moving average price is $2.52.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to analysts’ expectations of $31.88 million. On average, analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Barry J. Simon sold 151,967 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the transaction, the director directly owned 3,091,604 shares in the company, valued at approximately $22,259,548.80. This represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total transaction of $187,750.00. The SEC filing for this sale provides additional information. Insiders sold a total of 226,967 shares of company stock worth $1,531,912 over the last three months. Insiders own 69.48% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

Hedge funds have recently bought and sold shares of the company. TigerOak Management L.L.C. purchased a new stake in ImmunityBio during the fourth quarter worth about $33,000. Wealth Management Associates Inc. acquired a new position in shares of ImmunityBio in the fourth quarter valued at approximately $38,000. Cherry Creek Investment Advisors Inc. purchased a new stake in ImmunityBio during the 4th quarter worth approximately $28,000. MOR Wealth Management LLC acquired a new stake in ImmunityBio during the 4th quarter worth approximately $494,000. Finally, Hennion & Walsh Asset Management Inc. boosted its position in ImmunityBio by 31.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 402,639 shares of the company’s stock valued at $797,000 after buying an additional 95,855 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.